Objective: Disruption of vitamin D signaling in rodents causes activation of the rennin-angiotensin system (RAS) and development of hypertension. Observational studies in humans found lower circulating 25-hydroxyvitamin D [25(OH)D] is associated with increased RAS activity and blood pressure (BP). We performed the first randomized control trial to investigate the effects of vitamin D supplementation on the RAS in humans.
INTRODUCTION

L ower levels of 25-hydroxyvitamin D [25(OH)D]
are strongly and independently associated with an increased risk of developing hypertension [1] . Consistent with these findings, animal and human studies suggest that vitamin D deficiency may increase activity of the rennin-angiotensin system (RAS), both systemically and in the kidney. In mice, knock out of either the vitamin D receptor or the 1 a-hydroxylase gene [which converts 25(OH)D to 1,25(OH)D] upregulates RAS activity and induces hypertension [2, 3] , and treatment of such mice with 1,25-dihydroxyvitamin D suppresses RAS activity [3] . Human data support these findings. Individuals with low 25(OH)D levels have increased systemic and kidneyspecific RAS activation, whereas hypertensive individuals with polymorphisms in the vitamin D receptor also have increased RAS activation [4] [5] [6] [7] . In addition, a small open label and uncontrolled study of obese study participants with vitamin D deficiency found that treatment with ergocalciferol reduced kidney-specific RAS activity and blood pressure (BP) [8] . Thus, RAS activation may be a mechanism linking vitamin D with incident hypertension. However, there have been no randomized controlled trials that have examined this question.
We therefore performed a randomized, double-blind, placebo-controlled trial to evaluate the effects of ergocalciferol (50 000 IU/week) for 8 weeks on kidney-specific and systemic RAS activation in a population of overweight or obese individuals with vitamin D deficiency. Overweight and obese individuals were selected as they represent a clinically important population in which to study the effect of vitamin D repletion on BP. These individuals constitute approximately two-thirds of the adult US population, have increased RAS activity, are at increased risk for the development of hypertension, and are more likely to have vitamin D insufficiency relative to lean individuals [9, 10] . Significantly, the relationship between high BMI and elevated RAS activity appears to be attenuated among individuals who are vitamin D replete [5] .
METHODS
Study population
Participants were recruited from the greater Boston area from 2011 to 2014 using several mechanisms. First, we contacted participants through a Partners Healthcare database that included individuals who had previously expressed an interest in participating in clinical trials. Second, we recruited through local media outlets, such as billboards placed in nearby colleges and universities, local newspapers, and through online advertisement (such as Craiglist). Inclusion criteria were overweight or obese individuals (defined by a BMI !25 kg/m 2 ), with vitamin D deficiency [defined as serum 25(OH)D 20ng/ml] and no known history of hypertension. Study participants needed to have a screening SBP less than 140 mmHg, DBP less than 90 mmHg, and could not be taking BP lowering medications. Potentially eligible study participants were excluded if they were pregnant or had a history of diabetes, coronary artery disease, chronic kidney disease (defined as an estimated glomerular filtration rate using the modification of diet in renal disease estimating equation of less than 60 ml/min per 1.73 m 2 ) [11] , hypercalcemia, history of kidney stones, or a known active malignancy (except nonmelanoma skin cancer). All study participants provided written informed consent. The study was approved by the Institutional Review Board at Brigham and Women's Hospital.
Study design
The study flow of this randomized, double-blind, placebocontrolled trial is shown in Fig. 1 . After an initial phone screen, 489 individuals were asked to come in for a screening visit, in which a study physician explained the study and performed a detailed history and physical exam. Information about past medical history including medication use was obtained, as were measurements of BP, serum 25(OH)D, serum creatinine, liver function tests, and electrolytes. In total 93 individuals who meet eligibility criteria and provided informed consent underwent concealed 1 : 1 randomization, stratified by race and sex, using a computer based algorithm to be treated with ergocalciferol 50 000 IU or matching placebo, once weekly for 8 weeks. The unblinded research pharmacist, who supervised the randomization and provided study participants with study medication, formulated all pills (active treatment and placebo) to be physically indistinguishable (i.e. sight, smell, and weight). All other individuals involved in the study were blinded, including the investigators, study participants, outcome assessors, and data analyzers.
Study measurements
Following the screening visit, willing, and eligible study participants were scheduled for three more visits, including a baseline visit (after which study medication was provided), a checkup visit at 4 weeks, and a final visit at 8 weeks (after which study medication was discontinued). At the baseline and 8-week visits, study participants were admitted to the hospital and underwent measurement of kidney-specific and systemic RAS activity; after discharge, 24-h ambulatory BP was assessed.
Kidney-specific rennin-angiotensin system Participants underwent salt loading 3 days prior to RAS measurement at baseline and at 8 weeks of treatment. The change in RPF in response to captopril is a measure of the vasodilator effect from inhibiting angiotensin II (AngII)-mediated vascular tone and therefore the degree of kidneyspecific RAS activity. Although necessarily indirect, the bioassay of renal vasodilator responsiveness to inhibition of the RAS has been demonstrated to provide reproducible measures of renal-specific RAS activity in multiple studies, employing various agents in many patient subsets [12, 13] .
Systemic rennin-angiotensin system
During the first morning of each inpatient CCI visit, study participants remained supine for more than 60 min prior to blood collection for measurement of plasma renin activity (PRA) and serum AngII levels. PRA was measured by radioimmunoassay (Diasorin, Stillwater, Minnesota, USA). AngII was measured using a double-antibody radioimmunoassay (ALPCO, Salem, New Hampshire, USA). Both PRA and AngII assays were performed by the Brigham Research Assay Core (BRAC) with intraassay coefficients of variability (CVs) of 4.6-10% and interassay CVs of 5.6-7.6% for PRA, and intraassay CVs of 7.1-11.3% and interassay CV of 5.8-18.1% for AngII.
Ambulatory blood pressure measurement
Upon discharge from the CCI (following the baseline and 8 week in-patient visits), all study participants were fitted with an ambulatory BP monitor (Space-Labs 90207 Ambulatory BP Device, Redmond, Washington, USA) that was to be worn for 24 h. The monitors were preset to measure SBP and DBP every 30 min from 06 : 00 to 20 : 00 and every 60 min from 22 : 00 to 06 : 00. Each participant recorded in a sleep diary the time that they went to bed in the evening and the time that they rose in the morning. A 24-h ambulatory measurement was considered complete if at least 70% of the programmed BP measurements were successfully recorded, as has previously been described [14] . We assessed the change in mean 24-hour systolic blood pressure with treatment assignment defined as the mean 24-hour systolic blood pressure at 8 weeks minus the 24-hour systolic pressure at baseline for each subject. In each case, mean 24-h SBP was the average of all SBP readings recorded during the 24-h period following discharge from the CCI. Mean DBP, mean asleep SBP, and percentage nocturnal dipping were secondary outcomes. Mean awake and asleep SBPs were defined as the average of SBPs during the periods of wakefulness and sleeping per participant's sleep diary. Nocturnal dipping was defined as the difference in mean awake SBP and mean asleep SBP divided by mean awake BP.
Other measurements
Demographic, clinical, and laboratory data were obtained at the outpatient screening visit. Serum 25(OH)D was measured at screening visit, baseline inpatient visit, 4-week checkup visit, and at the 8-week follow-up inpatient visit. All serum 25(OH)D measurements were performed using the LIAISON direct competitive chemlluminescent immunoassay (DiaSorin, Stillwater, Minnesota, USA) with an intraassay CV of 5.4% and an interassay CV of 10.6%.
Statistical analysis
The distribution of baseline characteristics in each treatment group was assessed to describe the population recruited and to confirm effective randomization of study participants; t-tests were used to assess differences in continuous characteristics by treatment group, and x 2 tests were used for categorical variables. The effect of treatment assignment on serum 25(OH)D levels at baseline, 4 weeks and 8 weeks of treatment was analyzed using t-tests. We compared mean kidney-specific RAS (RPF response to captopril), systemic RAS (levels of PRA and AngII), and 24-h ambulatory BP at baseline and at 8 weeks within each treatment arm using paired t-tests. We tested for the effect of treatment assignment (ergocalciferol versus placebo) on changes in these endpoints using repeated measures analysis.
In sensitivity analyses, we compared the baseline characteristics of study participants who completed the study with those who failed to complete the 8-week study. In addition, we evaluated the association of the 8-week change in serum 25(OH)D level with corresponding change in RAS and ambulatory BP measures from baseline to 8 weeks. Statistical significance was set for P > 0.05. All analyses were performed using the SAS statistical package (version 9.4; SAS Institute Inc, Cary, North Carolina, USA).
Sample size calculations were performed assuming the SDs for SBP and DBP were 8 and 6 mmHg. With 45 participants allocated to each treatment, and assuming 10% drop out (final N ¼ 40 per group), we expected to have 80% statistical power to detect a treatment difference of 5.0 mmHg in SBP and 3.8 mmHg in DBP at a two-sided 0.05 significance level using repeated measures analysis.
RESULTS
A total of 489 individuals were screened. Of these, 93 eligible to participants were randomized (46 to ergocalciferol and 47 to placebo; Fig. 1 ). From those randomized, 84 study participants completed the study and were analyzed (43 assigned ergocalciferol and 41 assigned placebo). Five study participants discontinued the study prior to receiving study medication (three and one, respectively, in the ergocalciferol and placebo groups who did not complete the baseline visit, and one in the placebo group who developed hypertension prior to the baseline visit). Four study participants in the placebo group discontinued the study prior to the 8-week visit, including one who was lost to follow-up and three who dropped out.
The randomized population had a mean age of 37 (AE12) years and a mean BMI of 33.9 AE 5.6 kg/m 2 . The population was 67% female and 33% black. At baseline, the mean 25(OH)D level was 14.5 AE 5.5 ng/ml, the mean BP was 118/77 AE 10/8 mmHg, and the mean estimated glomerular filtration rate was 108 AE 20 ml/min per 1.73 m 2 . There was no significant difference in any of the baseline characteristics between the ergocalciferol and placebo groups, including baseline BP and serum 25(OH)D levels ( Table 1) .
Serum levels of 25(OH)D substantially improved with ergocalciferol. Baseline 25(OH)D increased from a mean of 14.7 AE 5.4 ng/ml to 27.8 AE 8.1 ng/ml at 4 weeks and to 30.3 AE 7.5 ng/ml at 8 weeks. In contrast, mean 25(OH)D in the placebo group was 14.3 AE 5.6 at baseline, 16.8 AE 15.5 at 4 weeks, and 17.4 AE 18.8 at 8 weeks. A statistically significant separation in 25(OH)D levels between the treatment groups was apparent by 4 weeks and persisted at 8 weeks (P < 0.0001, Fig. 2) . Correction of vitamin D deficiency (to a level above 20 ng/ml) was achieved in 95% of study participants assigned ergocalciferol and 22% of study participants assigned placebo (P value < 0.0001). Of the 84 study participants who completed the study for measurement of kidney-specific RAS (43 in the ergocalciferol group and 41 in the placebo group), ambulatory BP monitoring was analyzed in 56 (67%) who had more than 70% of the programmed BP measurements successfully recorded at both the baseline and 8-week visits (29 and 27 in the ergocalciferol and placebo groups, respectively).
There were no clinically significant or statistically significant differences in the primary outcome, change in kidney-specific RAS activity, between baseline and 8-weeks follow-up in either treatment group. The response of RPF to captopril was measured as 33.9 AE 56.1 ml/min per 1.73 m 2 at baseline and 35.7 AE 47.7 ml/min per 1.73 m 2 at 8 weeks in the ergocalciferol group (P value ¼ 0.83); in the placebo group it was 37.3 AE 46.9 ml/min per 1.73 m 2 at baseline and 35.9 AE 26.2 ml/min per 1.73 m 2 at 8 weeks (P value ¼ 0.78). There was no difference between the 8-week change in RPF response with ergocalciferol and the corresponding 8-week change with placebo (P value ¼ 0.72, Table 2 ). Systemic RAS activity measured by PRA did not change significantly following 8 weeks of treatment with either ergocalciferol (from 0.34 AE 0.37 ng/ml per h to 0.36 AE 0.44 ng/ml per h, P value ¼ 0.72) or placebo (0.42 AE 0.44 ng/ml per h to 0.44 AE 0.80 ng/ml per h; P value ¼ 0.85). Similarly, serum AngII levels did not change significantly after 8 weeks of treatment with either ergocalciferol or placebo. 
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There was no significant change in mean 24-h SBP or other ambulatory measurements following treatment with either ergocalciferol or placebo (Table 3) . In sensitivity analyses, individual's changes in RPF or BP measurements between baseline and 8 weeks were not correlated with changes in serum 25(OH)D during the same period (Table 4) .
Adverse events did not differ significantly between treatment arms (Table 5 ). The most common adverse event was abdominal discomfort, which occurred in five and four study participants in the ergocalciferol and placebo arms, respectively.
DISCUSSION
In this randomized, placebo-controlled trial, we found that correcting vitamin D deficiency in obese individuals with vitamin D deficiency without hypertension neither reduced kidney-specific or systemic RAS activity nor lowered BP. These findings suggest that low vitamin D levels are not a modifiable risk factor for increased RAS activity or development of hypertension.
Considerable epidemiological data have demonstrated a robust association of low serum levels of vitamin D with risk of hypertension [1] . Consistent with these findings, animal studies found that vitamin D receptor knock out mice had increased renin activity, increased circulating AngII levels, and developed hypertension that could be reversed with RAS blockade [2, 15, 16] . In separate studies, mice unable to activate 25(OH)D because of 1-alpha-hydroxylase deficiency exhibited a similar phenotype as animals lacking the vitamin D receptor [3] . In this model, supplementation with 1,25(OH) 2 D reversed the phenotype, supporting the role of vitamin D in RAS activation and the development of hypertension. Detailed animal experiments have shown that vitamin D increases the intracellular calcium concentrations leading to decreased renin secretion from the juxtaglomerular apparatus [17] .
Human cross-sectional studies support the association of low serum vitamin D levels with upregulation of RAS activity. The largest of these (N ¼ 3296) found that PRA levels were significantly higher in those with vitamin D deficiency, defined by 25(OH)D levels less than 20 mg/l, as compared with those whose levels were more than 30 mg/l (plasma renin concentration 12.0 versus 10.8 pg/ml, P value ¼ 0.004), as were plasma AngII concentrations (21.0 ng/ ml versus 18.0 ng/ml, P value < 0.001) [18] . In a smaller study, where renal-specific RAS activity was measured as the RPF response in AngII infusion, individuals with lower serum 25(OH)D levels had higher renal-specific RAS activity with lower serum 25(OH)D levels [4] . However, only one study has examined the effect of correcting vitamin D deficiency on RAS activation. In that open-label study of 14 obese study paricipants with hypertension and serum 25(OH)D levels less than 25 ng/ml, treatment with ergocalciferol (15 000 IU daily for 4 weeks) reduced kidneyspecific RAS activation, measured as the renal-vascular sensitivity to AngII. Baseline RPF increased by 5% (P value < 0.01) following an increase in mean serum 25(OH)D levels from 18.2 AE 1.8 ng/ml to 51.9 AE 3.1 ng/ml. There was also an increased response in RPF to AngII infusion following treatment with ergocalciferol (P value < 0.05). These changes in RPF suggested there is decreased constitutive kidney-specific RAS activity with increased 25(OH)D levels, and that low vitamin D is a modifiable risk factor for increased RAS activity [8] .
In contrast to this prior open-label uncontrolled study, the current study, which is a larger, double-blinded placebo-control trial, revealed no change in kidney-specific or systemic RAS activity with successful correction of vitamin D deficiency. Compared with the open-label study, we recruited individuals who had similar baseline 25(OH)D levels and BMI, but who were younger, had lower baseline BP and higher baseline RPF. These differences in baseline characteristics (BP and RPF) may indicate that our population had lower baseline RAS activation, potentially explaining differences between the studies. The current trial also used a lower dose of ergocalciferol to replete vitamin D than the open label study (50 000 IU per week as compared with 15 000 IU per day), and consequently produced a less dramatic increase in 25(OH)D levels (which increased from 18 to 52 ng/ml in the open label study), despite treating for a longer period of time. However, unless increasing serum 25(OH)D above a threshold level (between 30 and 52 ng/ml) is required to have an effect on RAS activity, then our trial of 84 participants, three times larger than the open label trial, would be expected to detect an effect of vitamin D supplementation on RAS activity. Perhaps more likely is that the smaller and uncontrolled intervention produced a spurious finding that was not be reproduced by the current randomized, controlled trial.
In addition to the lack of effect on the RAS, we also did not find an effect of vitamin D supplementation on BP. Genetic analyses, specifically Mendelian randomization studies, found that individuals with genetically lower serum 25(OH)D levels have an increased incidence of hypertension, implying that vitamin D deficiency may play a role in the development of hypertension [19] . However, most but not all interventional studies show no BP benefit from repleting with vitamin D. To date, there have been over 50 randomized, placebo-controlled trials of vitamin D supplementation that reported BP as an outcome [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [20] . The results of our study, in which ambulatory BP was measured at baseline and at 8 weeks are consistent with this recent meta-analysis and suggests that vitamin D supplementation does not improve any ambulatory BP parameter, including nocturnal BP and nocturnal dipping.
The discrepancy between Mendelian randomization studies and clinical trials may result from vitamin D having a relatively small effect on BP. As an example, the largest genetic analysis included 142 255 individuals, and found that a 10% increase in genetically determined 25(OH)D concentration was associated with a 0.37 mmHg lower SBP (95% confidence interval, 0.003-0.73 mmHg lower) [19] . Thus, for a randomized clinical trial to have adequate statistical power to detect such a small benefit on BP, tens of thousands of individuals would need to be recruited and followed for many years; such a study is unlikely to be performed. The largest trial is still ongoing [VITAL Hypertension Trial (ClinicalTrials.gov Identifier NCT01653678)], in which 25 874 men and women have been recruited to take 2000 IU of cholecalciferol or placebo per day for up to 5 years. However, VITAL is not powered to detect such small effects on BP which, even if real, would be of marginal clinical importance.
Our study has several limitations that deserve mention. First, we recruited individuals with serum 25(OH)D levels less than 20 ng/ml, and it may be that a more vitamin D deficient population would have had a greater response to correction of 25(OH)D levels. However, several of the observational studies that described an association between low 25(OH)D levels and increased incidence of hypertension included individuals with 25(OH)D levels similar to those in this study. Second, we chose to replete low serum 25(OH)D levels using ergocalciferol, and it is possible that active vitamin D analogues would have produced to a measurable response. However, using active vitamin D analogues would have been an unconventional approach to treating low serum 25(OH)D levels in individuals with The effect of vitamin D on blood pressure
Journal of Hypertension www.jhypertension.comnormal renal function, and would likely have lead to more adverse events specifically hypercalcemia. In addition, the previous unblinded study found significant effects of conventional vitamin D supplements (rather than active vitamin D) on the endpoints that we measured. Third, it is possible that low serum 25(OH)D levels may not necessarily identify individuals with low levels of bioactive vitamin D, because of interindividual differences in vitamin Dbinding protein [32] . Some of the individuals recruited may have had low levels of vitamin D-binding protein with low total but normal (or even high) bioactive 25(OH)D concentrations, such that supplementation would be expected to have no effect [32] . Finally the 8-week duration of treatment may have been inadequate to affect RAS activity or BP. Although we were able to replete serum 25(OH)D levels to normal levels in the treatment group by 8 weeks, it is possible that the full effects of repletion on the RAS and BP require a longer period of correction. However, this possibility is unlikely given the short duration of the one prior study that found a benefit on RAS activity and of several prior trials that found benefits on BP.
We conclude that in contrast to animal experiments, observational studies, and open-label uncontrolled interventions, this randomized, double-blind, placebo-controlled trial found no effect of vitamin D supplementation on RAS activity or BP in vitamin D deficient individuals.
Reviewers' Summary Evaluations
Referee 1
The authors performed a randomized clinical study to examine the effects of VitD (ergocalciferol) on renal and systemic RAS activity as well as ambulatory BP in obese subjects with low circulating VitD levels. In contrast to the results of a preceding study (Vaidya A, et al. J Clin Endocrine Metab, 97: 2456-65, 2012), the authors did not find significant effects of ergocalciferol not only on renal and systemic RAS activity but also on ambulatory BP in these subjects, in spite of a modest increase in the circulating VitD levels in comparison to placebo. The results are interesting and important for understanding the pathophysiology of hypertension with obesity.
Referee 2
Vitamin D repletion could be an interesting target to improve blood pressure control, especially in the overweight-obese population, where vitamin D levels are largely insufficient. This randomized placebo-controlled clinical trial of 8 weeks treatment with ergocalciferol in overweight individuals without hypertension found no difference in kidney-specific RAS activity and ambulatory blood pressure levels. Although conclusions about the utility of long-term vitamin D supplementation are not definitive, in the short term different approaches should be considered in this high-risk population.
